Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib
- 1 December 2019
- journal article
- research article
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 74, 108227
Abstract
No abstract availableKeywords
Funding Information
- National Science Council (101-2313-B-003-002-MY3)
- Ministry of Science and Technology, Taiwan
- National Taiwan Normal University
This publication has 36 references indexed in Scilit:
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer ModelsCancer Cell, 2013
- Evaluation of regorafenib in colorectal cancer and GISTThe Lancet, 2013
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Synthetic lethality: General principles, utility and detection using genetic screens in human cellsFEBS Letters, 2010
- Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemiaBlood, 2008
- Multi-target therapeutics: when the whole is greater than the sum of the partsDrug Discovery Today, 2007
- Justicidin A decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cellsCarcinogenesis, 2005
- Isotype-Specific Functions of Raf KinasesExperimental Cell Research, 1999
- Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-kB-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular TransformationJournal of Biological Chemistry, 1996
- Cytochemical observation of regulated bacterial beta-galactosidase gene expression in mammalian cells.Proceedings of the National Academy of Sciences, 1989